Filing Manager
ORBIMED ADVISORS LLC
Reporting Manager
ORBIMED ADVISORS LLC
Symbol
CMPX
Shares outstanding
138,363,582 shares
Disclosed Ownership
15,219,994 shares
Ownership
11%
Form type
SCHEDULE 13D/A
Filing time
11 Apr 2025, 19:21:13 UTC
Date of event
09 Apr 2024
Next filing
15 Aug 2025

Quoteable Key Fact

"ORBIMED ADVISORS LLC disclosed 11% ownership in Compass Therapeutics, Inc. COMMON STOCK (CMPX) on 09 Apr 2024."

Quick Takeaways

  • ORBIMED ADVISORS LLC filed SCHEDULE 13D/A for Compass Therapeutics, Inc. COMMON STOCK (CMPX).
  • Disclosed ownership: 11%.
  • Date of event: 09 Apr 2024.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 11 Apr 2025, 19:21.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Source Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (4)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
ORBIMED ADVISORS LLC 11% 15,219,994 0 15,219,994 /s/ Carl L. Gordon Carl L. Gordon/Member 0001055951
ORBIMED CAPITAL GP V LLC 11% 15,219,994 0 15,219,994 /s/ Carl L. Gordon Carl L. Gordon/Member of OrbiMed Advisors LLC 0001615374
OrbiMed Genesis GP LLC 0% 0 0 0 /s/ Carl L. Gordon Carl L. Gordon/Member of OrbiMed Advisors LLC 0001808744
ORBIMED CAPITAL LLC 0% 0 0 0 /s/ Carl L. Gordon Carl L. Gordon/Member 0001157524
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .